November 2023—Werfen announced FDA 510(k) clearance of its Aptiva Connective Tissue Disease Essential reagent, to aid in diagnosing connective tissue disease. The Aptiva CTD Essential complements Werfen’s previously cleared Aptiva Celiac Disease reagent.
Read More »Werfen completes acquisition of Immucor
August 2023—Werfen announced it has completed the acquisition of Immucor after obtaining all necessary regulatory and antitrust approvals. The purchase price was about $2 billion.
Read More »Werfen completes acquisition of Immucor
July 27, 2023—Werfen announced it has completed its acquisition of Immucor after obtaining all necessary regulatory and antitrust approvals.
Read More »IMV awards Werfen five ServiceTrak awards
February 2023—Werfen has received five 2022 IMV ServiceÂTrak clinical laboratory awards in two categories. The company received best system performance and best service awards in the coagulation analyzers category, and awards for best customer satisfaction, best system performance, and best service in the blood gas category. This is the fourth consecutive year Werfen has been recognized in coagulation and the second time it has received all three awards in the blood gas category.
Read More »Werfen to acquire Immucor
Nov. 4, 2022—Werfen announced it has agreed to acquire Immucor from asset management firm TPG.
Read More »Werfen companies now under one name, brand
August 2021—Werfen announced that its companies, including Instrumentation Laboratory, Inova Diagnostics, and Biokit, are uniting under one name and one brand—Werfen—and a new corporate logo.
Read More »Werfen companies now under one name, brand
July 15, 2021—Werfen announced that its companies, including Instrumentation Laboratory, Inova Diagnostics, and Biokit, are uniting under one name and one brand—Werfen—and a new corporate logo.
Read More »